[Hyperlipidemia: What role do PCSK9 inhibitors play?]

Area of Science:

• Cardiology
• Pharmacology

Background:

• Statins and ezetimibe are foundational therapies for cholesterol management.
• Achieving target LDL cholesterol levels remains crucial for cardiovascular risk reduction.

Purpose of the Study:

• To summarize current clinical recommendations for PCSK9 inhibitor utilization.
• To define the role of PCSK9 inhibitors in conjunction with existing lipid-lowering therapies.

Main Methods:

• Review of current clinical guidelines and recommendations.
• Analysis of patient populations benefiting from PCSK9 inhibitors.

Main Results:

• PCSK9 inhibitors are indicated for very high cardiovascular risk patients needing >50% LDL-C reduction despite maximal statin/ezetimibe therapy.
• They are also considered for familial hypercholesterolemia and statin intolerance in high-risk individuals.

Conclusions:

• PCSK9 inhibitors represent a valuable, safe addition to the lipid-lowering armamentarium.
• Strategic use of PCSK9 inhibitors is essential for optimizing cardiovascular risk management in specific patient groups.